Eduardo Castañón Álvarez

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

Carlos Gomez‐Roca, Eduardo Yáñez, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2021 · 68 citations

Medicine, Oncology, Pharmacology +12

Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)

Ignacio Melero, Eduardo Castañón Álvarez, Morten Mau‐Sørensen et al. · Annals of Oncology · 2018 · 19 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +7

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

Carlos Gomez‐Roca, Eduardo Yáñez, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2021 · 18 citations

Medicine, Oncology, Pharmacology +12

Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.

Kristoffer Staal Rohrberg, Mariana Brandão, Eduardo Castañón Álvarez et al. · Journal of Clinical Oncology · 2023 · 18 citations · Full text

Medicine, Oncology, Pharmacology +17

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.

Hyun Cheol Chung, Zarnie Lwin, Carlos Gomez‐Roca et al. · Journal of Clinical Oncology · 2021 · 17 citations

Medicine, Pharmacology, Pharmacotherapy +17